



The DowDuPont Specialty Products Division: A Technology-Driven Innovation Leader

Innovation leader composed of technology-driven specialty businesses with highly-differentiated products and solutions that transform industries and everyday life


KEY CAPABILITIES

DIVISION OVERVIEW

Name: Specialty Products Division
Chief Operating Officer: Marc Doyle
Headquarters: Wilmington, Delaware

- World-class product innovation and application development capabilities to help customers solve complex problems in the electronics, transportation, building and construction, health and wellness, food, personal care, safety and consumer goods industries
- Broad portfolio of market-leading offerings and brands, proprietary and differentiated technologies, and a robust pipeline
- Strong strategic marketing capabilities and comprehensive understanding of value chains and local markets
- Global scale and diversity to deliver on local needs and emerging growth segments

SPECIALTY PRODUCTS⁽¹⁾



HERITAGE PORTFOLIO MAKEUP

DUPONT

- DuPont Electronics & Communications
- DuPont Protection Solutions
- DuPont Nutrition & Health
- DuPont Industrial Biosciences
- DuPont Sustainable Solutions
- DuPont Performance Polymers
- FMC Health & Nutrition⁽³⁾

DOW

- Dow Electronic Materials
- Dow Automotive Systems' adhesives and fluids platforms
- Dow Building Solutions
- Dow Water and Process Solutions
- Dow Pharma and Food Solutions
- Dow Microbial Control
- Several silicones-based businesses aligned with applications in industrial LED, semiconductors, medical, as well as Molykote[®] brand lubricants for automotive and industrial equipment and Multibase Inc, which provides solutions for the thermoplastic compounding industry

TECHNOLOGY LEADERSHIP


- Functional materials technologies and precision patterning
- Probiotics, nutrition, microbiome and fermentation sciences
- Protein and metabolic pathway engineering
- Manufacturing and process engineering
- Formulation science and development
- Advanced polymer, fiber, film, membrane and compounded resin technologies

(1) Based on Dow's and DuPont's Net Sales as reported in each company's 2016 Form 10-K filing. (2) Includes revenue associated with health and nutrition assets to be acquired from FMC. (3) DuPont's acquisition of substantially all of FMC's Health & Nutrition business is expected to close in the fourth quarter of 2017, subject to customary closing conditions, including regulatory approvals.

*Mr. Liveris will remain on the Advisory Committee until his previously announced retirement from the company on July 1, 2018.

INNOVATION-DRIVEN BUSINESS MODEL AND CUSTOMER-ORIENTED APPROACH, STRENGTHENED BY RICH HERITAGE OF BRINGING TRANSFORMATIONAL NEW PRODUCTS AND INSIGHTS TO MARKETS

MARKET-LEADING BUSINESSES AND TRUSTED BRANDS

	Leading Positions and Brands	End Markets
 <p>ELECTRONICS & IMAGING</p>	<ul style="list-style-type: none"> Advanced printing materials Circuit packaging materials Display materials Semiconductor fabrication materials Solar/photovoltaic materials Kapton®, Cyrel®, Tedlar®, IKONIC™ 	<ul style="list-style-type: none"> Aerospace Automotive Consumer electronics Military Printing Solar energy Semiconductors
 <p>SAFETY & CONSTRUCTION</p>	<ul style="list-style-type: none"> Aramid fibers and paper Insulation, caulks and sealants Nonwoven structures Protective garments Separation and purification technology Tyvek®, Kevlar®, Nomex®, Corian® Styrofoam™, Great Stuff™ SUSTAINABLE SOLUTIONS 	<ul style="list-style-type: none"> Aerospace Automotive Construction Consumer goods Medical packaging Military, law enforcement and emergency response Oil and gas Water purification
 <p>NUTRITION & BIOSCIENCES⁽¹⁾</p>	<p>NUTRITION & HEALTH</p> <ul style="list-style-type: none"> Probiotics and cultures Specialty proteins Systems and texturants Excipients Danisco®, Howaru®, Methocel™, Avicel® <p>INDUSTRIAL BIOSCIENCES</p> <ul style="list-style-type: none"> Biomaterials and biofuels Industrial enzymes Microbial technologies Sulfuric acid technology Sorona®, Bio-PDO™, MECS®, BELCO®, STRATCO®, Silvadur™, Kathon™ 	<p>NUTRITION & HEALTH</p> <ul style="list-style-type: none"> Child nutrition Dietary supplements Food and beverage Pharmaceuticals Sports nutrition <p>INDUSTRIAL BIOSCIENCES</p> <ul style="list-style-type: none"> Animal nutrition Biofuels Carpet and apparel Cleaning and personal care Fertilizer Food and beverage Oil and gas
 <p>TRANSPORTATION & ADVANCED POLYMERS</p>	<ul style="list-style-type: none"> Adhesives High performance polymers Compounded resins Brake fluids, lubricants and medical silicones Zytel®, Hytrel®, Kalrez®, Molykote®, BetaSeal®, Vespel® 	<ul style="list-style-type: none"> Aerospace Automotive Consumer electronics Consumer goods Medical devices Oil and Gas Semiconductors

ATTRACTIVE GROWTH, INNOVATION AND VALUE DRIVERS

Connectivity & Functionality

Protection & Sustainable Development

Emerging Needs in New Geographies

Health & Nutrition

Renewable Energy & Materials

Lightweighting & Composites

(1) Includes capabilities that will be added through planned acquisition of FMC's Health & Nutrition business.
 ®™ Trademark of DowDuPont, The Dow Chemical Company, E.I. du Pont de Nemours and Company, or their affiliates.

Cautionary Statement About Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words.

On December 11, 2015, The Dow Chemical Company (“Dow”) and E. I. du Pont de Nemours and Company (“DuPont”) announced entry into an Agreement and Plan of Merger, as amended on March 31, 2017, (the “Merger Agreement”) under which the companies would combine in an all-stock merger of equals transaction (the “Merger Transaction”). Effective August 31, 2017, the Merger Transaction was completed and each of Dow and DuPont became subsidiaries of DowDuPont Inc (“DowDuPont”). For more information, please see each of DowDuPont’s, Dow’s and DuPont’s latest annual, quarterly and current reports on Forms 10-K, 10-Q and 8-K, as the case may be, and the joint proxy statement/prospectus included in the registration statement on Form S-4 filed by DowDuPont with the SEC on March 1, 2016 (File No. 333-209869), as last amended on June 7, 2016, and declared effective by the SEC on June 9, 2016 (the “Registration Statement”) in connection with the Merger Transaction.

Forward-looking statements by their nature address matters that are, to different degrees, uncertain, including the intended separation of DowDuPont’s agriculture, materials science and specialty products businesses in one or more tax efficient transactions on anticipated terms (the “Intended Business Separations”) and the proposed transaction with FMC Corporation, in which, among other things, FMC will acquire a portion of DuPont’s Crop Protection business and DuPont will acquire substantially all of FMC’s Health and Nutrition business (the “FMC Transaction”). Forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future events which may not be realized. Forward-looking statements also involve risks and uncertainties, many of which are beyond the company’s control. Some of the important factors that could cause DowDuPont’s, Dow’s or DuPont’s actual results to differ materially from those projected in any such forward-looking statements include, but are not limited to: (i) successful integration of the respective agriculture, materials science and specialty products businesses of Dow and DuPont, including anticipated tax treatment, unforeseen liabilities, future capital expenditures, revenues, expenses, earnings, synergies, economic performance, indebtedness, financial condition, losses, future prospects, business and management strategies for the management, expansion and growth of the combined operations; (ii) impact of the divestitures required as a condition to consummation of the Merger Transaction as well as other conditional commitments; (iii) the completion of the FMC Transaction on anticipated terms and timing, including the possibility that the FMC Transaction may not close and the anticipated benefits thereof may not be obtained; (iv) achievement of the anticipated synergies by DowDuPont’s agriculture, materials science and specialty products businesses; (v) risks associated with the Intended Business Separations, including those that may result from the comprehensive portfolio review undertaken by the DowDuPont board, changes and timing, including a number of conditions which could delay, prevent or otherwise adversely affect the proposed transactions, including possible issues or delays in obtaining required regulatory approvals or clearances related to the Intended Business Separations, disruptions in the financial markets or other potential barriers; (vi) the ability of DowDuPont and DuPont to integrate FMC’s Health and Nutrition business and to achieve anticipated synergies; (vii) the risk that disruptions from the Intended Business Separations and the FMC Transaction will harm DowDuPont’s business (either directly or as conducted by and through Dow or DuPont), including current plans and operations; (viii) the ability to retain and hire key personnel; (ix) potential adverse reactions or changes to business relationships resulting from the completion of the merger, the Intended Business Separations, and the FMC Transaction; (x) uncertainty as to the long-term value of DowDuPont common stock; (xi) continued availability of capital and financing and rating agency actions; (xii) legislative, regulatory and economic developments; (xiii) potential business uncertainty, including changes to existing business relationships, during the pendency of the Intended Business Separations and the FMC Transaction that could affect the company’s financial performance; (xiv) certain restrictions during the pendency of the FMC Transaction that may impact DuPont’s ability to pursue certain business opportunities or strategic transactions; and (xv) unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as management’s response to any of the aforementioned factors. These risks, as well as other risks associated with the merger, the Intended Business Separations, and the FMC Transaction, are or will be more fully discussed in (1) the Registration Statement and (2) in the current, periodic and annual reports filed with the SEC by DowDuPont and to the extent incorporated by reference into the Registration Statement, by Dow and DuPont, and/or (3) DuPont’s and Dow’s most recently filed Form 10-K, 10-Q and 8-K reports. While the list of factors presented here is, and the list of factors presented in the Registration Statement are, considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on DowDuPont’s, Dow’s or DuPont’s consolidated financial condition, results of operations, credit rating or liquidity. None of DowDuPont, Dow or DuPont assumes any obligation to publicly provide revisions or updates to any forward-looking statements regarding the proposed transaction and intended business separations, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.